Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of entity ABN
Cynata Therapeutics Limited
98 104 037 372
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Dr Paul K Wotton |
Date of last notice | 25 September 2018 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest |
|
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Citicorp Nominees Pty Limited (beneficial interest) |
Date of change | 25 October 2018 |
No. of securities held prior to change | 1. 100,000 Ordinary Sharse 100,000 Unlisted Options - Exercise Price $1.022 Expiry 17 November 2019 2,000,000 Unlisted Options - Exercise Price $1.50 Expiry 17 November 2019 2. 55,000 Ordinary Shares |
Class | Ordinary Shares |
Number acquired | 2. 100,000 Ordinary Shares |
Number disposed | 1. 100,000 Ordinary Shares |
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation | N/A |
No. of securities held after change | 1. 100,000 Unlisted Options - Exercise Price $1.022 Expiry 17 November 2019 2,000,000 Unlisted Options - Exercise Price $1.50 Expiry 17 November 2019 2. 155,000 Ordinary Shares |
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Transfer of shares held in direct holding to shares held in indirect holding. No change in beneficial ownership. |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | N/A |
Nature of interest | N/A |
Name of registered holder (if issued securities) | N/A |
Date of change | N/A |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
Interest acquired | N/A |
Interest disposed | N/A |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
Interest after change | N/A |
Part 3 - +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
If prior written clearance was provided, on what date was this provided? | N/A |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Attachments
- Original document
- Permalink
Disclaimer
Cynata Therapeutics Ltd. published this content on 26 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 October 2018 01:31:09 UTC